0001645113-25-000042
SEC filingNovoCure's Q3 2025 revenue grew 8% to $167.2M, led by France and Germany, but gross margin compressed to 73% due to inventory provision and tariffs.
NovoCure's net revenues for Q3 2025 increased 8% to $167.2 million from $155.1 million in Q3 2024, driven by continued growth in France ($4.4 million increase) and Germany ($3.3 million increase from active patient growth and reimbursement improvements). Other international markets contributed $4.4 million, including early commercialization in Spain and aged receivables in the UK. Exchange rate benefits added $3.3 million. These gains were partially offset by a $1.7 million reduction in U.S. revenue due to fewer one-time prior period claim benefits. Optune Lua revenue reached $3.1 million, split between NSCLC ($1.6 million) and MPM ($1.5 million).
Gross margin fell to 73% from 77%, primarily due to a $2.9 million inventory obsolescence provision for Optune Lua arrays and $1.5 million in higher tariffs. Cost of revenues increased 26% to $44.7 million, outpacing revenue growth. Excluding sales to Zai, cost per active patient per month rose 16% to $3,159.
Operating expenses increased 4% to $158.5 million. Research, development and clinical studies rose 4% to $54.0 million, driven by product development and regulatory costs for PANOVA-3 and METIS PMA filings, partially offset by lower direct clinical costs from trial completions. Sales and marketing declined 2% to $58.5 million due to lower share-based compensation, partially offset by marketing for NSCLC launch. General and administrative expenses rose 15% to $45.9 million, reflecting higher share-based compensation and investment in digital infrastructure.
Net loss widened to $37.3 million ($0.33 per share) from $30.6 million ($0.28 per share). Adjusted EBITDA turned negative to -$3.0 million from +$1.7 million, as revenue growth was outweighed by increased spending on new indications and prelaunch activities.
NovoCure operates as a single segment. Regional performance highlights: U.S. active patients remained flat at 2,280, while international active patients grew 12% to 2,136, led by Germany (626 from 570) and France (499 from 393). Optune Lua active patients surged to 139 from 33, with 100 NSCLC patients. Prescriptions for Optune Lua totaled 130 in Q3 2025 (109 NSCLC, 21 MPM), compared to 18 in Q3 2024 (0 NSCLC, 18 MPM). The revenue mix shifted toward international markets, which contributed a growing share due to reimbursement improvements and new launches.
Management expects operating expenses to continue increasing as the company expands into additional indications beyond CNS and lung, including pancreatic cancer (Optune Pax, PMA application filed) and brain metastases from NSCLC (Optune Mya, module filing in progress). Guidance on revenue or margins is not provided, but the company aims to balance growth with financial health. Key near-term catalysts: FDA decisions on Optune Pax and Optune Mya, and the impact of the U.S. government shutdown on regulatory timelines. The convertible note maturity of $560.9 million on November 1, 2025, will be a significant cash event. The Senior Secured Credit Facility provides up to $400 million, with Tranche A and B drawn ($200 million). The company believes its $1.03 billion cash position is sufficient for at least 12 months.
As of September 30, 2025, the company held $342.1M in cash and cash equivalents plus $691.4M in short-term investments, totaling $1.03B in liquid assets. Total debt stood at $755.2M, comprising $560.6M in convertible notes (due November 2025) and $194.6M drawn on the senior secured credit facility (net of issuance costs). The net debt-to-equity ratio is approximately 2.2x, considering shareholders' equity of $341.3M. Inventory increased to $39.1M from $35.1M at year-end 2024, reflecting continued investment in production.
The notes disclose no material purchase commitments beyond operating leases. Pledged deposits of $5.1M cover bank guarantees for operating facilities, and an additional €15.0M ($17.6M) of short-term investments is pledged as collateral for cash concentration agreements. Deferred revenue (short-term contract liabilities) totaled $15.7M, representing payments received in advance of performance obligations.
The company did not repurchase shares or pay dividends during the period. Financing activities included the drawdown of $99.9M (net) from the Tranche B Loan under the senior secured credit facility in September 2025, bringing total borrowings to $200.0M. Capital expenditures for property, equipment, and field equipment were $21.8M in the nine months ended September 30, 2025, down from $33.9M in the prior-year period, representing 4.5% of net revenues. The company continues to invest in R&D (expenses of $163.6M YTD) and sales & marketing ($171.4M).
The company operates as a single reportable segment. Geographic revenue breakdown (by patient location) shows U.S. revenues of $284.0M (59.0% of total), flat year-over-year. International markets (ex-Greater China) contributed $182.2M (37.9%), led by Germany ($58.1M), France ($55.9M), and Japan ($27.6M). Greater China (Zai Lab agreement) added $14.8M (3.1%). Note 6 provides detailed performance period revenue recognition: $461.6M recognized in the current period and $19.4M from prior periods.
In Q3 2025, NovoCure generated $20.6M in operating cash flow despite reporting a net loss of $37.3M. This divergence is primarily due to significant non-cash charges: share-based compensation of $29.3M, depreciation/amortization of $3.7M, and asset write-downs of $0.2M. Positive working capital changes (e.g., $24.8M increase in payables) further boosted cash flow. Capex of $5.7M was relatively modest, representing 28% of CFO, reflecting disciplined investment in field equipment. Free cash flow is not explicitly stated but would be approximately $14.9M (CFO minus capex). Investing activities provided net $71.4M, driven by $185M in maturities of short-term investments offset by $107.9M in purchases. Financing activities contributed $100.5M, largely from $99.98M in proceeds from a senior secured credit facility. Cash and equivalents rose by $192.5M to $344.6M. The strong operating cash flow, low capex intensity, and liquidity from financing indicate a solid cash generation profile, though reliance on debt and share issuance warrants monitoring.